Coinfections in COVID-19

Consent

By submitting this registration form, I understand and agree that Gilead Sciences (or its affiliates) may store, process and/or share my personal data provided above (e.g. full name, specialty, country and contact information) with:
(i) third party vendors who provide services to Gilead Sciences for the purposes of providing me with information about products, services or promotional materials that may be of an interest to me or for audit and monitoring exercises; or
(ii) Saudi government agencies to fulfil its disclosure reporting obligations under Transparency and Payments Disclosure Guidance of the Saudi Food and Drug Authority (available on: www.sfda.gov.sa).
Additionally, I consent to be contacted by Gilead Sciences (or its affiliates or third party vendors) by electronic means with information about WiFi (Webinars in Invasive Fungal Infections) or communication regarding future Gilead Sciences’ educational events.
Gilead shall remain responsible for the confidentiality and security of your personal data at all times.
You have the right to opt out of receiving such electronic communications, at any time, by contacting us at [email protected] *

This webinar is created for healthcare professionals only.
This webinar is fully funded and supported by Gilead Sciences.

For any technical questions relating to this webinar, please contact
[email protected]

For any questions related to Gilead products or therapeutic areas, please contact:
[email protected]

Reporting suspected adverse reactions after authorization of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via the national reporting schemes as applicable Adverse reactions may also be reported directly to the manufacturer of the suspected product. Adverse reactions related to Gilead products may be reported directly to Gilead via: [email protected] *